Antibody-Drug Conjugate– tag –
-
Repligen Acquires BioLife Solutions for ~$1.5B, Expanding Cell Therapy Services; Beone Medicines Invests $300M in US Manufacturing Expansion
Endpoints News USA Overview Repligen has announced the acquisition of cell processing service provider BioLife Solutions for approximately $1.5 billion, significantly broadening its capabilities within the cell therapy sector. Concurrent... -
First-in-Class EGFR-HER3 Bispecific ADC Iza-Bren Achieves 48.1% ORR in Phase Ib for Extensive-Stage Small Cell Lung Cancer
ASCO Publications USA Overview Results from a Phase Ib study of Izalontamab Brengitecan (Iza-Bren), the first-in-class EGFR-HER3 bispecific antibody-drug conjugate (ADC) for extensive-stage small cell lung cancer (SCLC), have been announ... -
Daiichi Sankyo & AstraZeneca’s Datroway Approved in EU as Only TROP2-Directed Medicine with Overall Survival Benefit for 1st-Line Metastatic TNBC Patients Ineligible for Immunotherapy
Business Wire USA Overview Datroway, a TROP2-directed antibody-drug conjugate (ADC) by Daiichi Sankyo and AstraZeneca, received EU approval for first-line treatment of metastatic triple-negative breast cancer (TNBC) patients not eligible... -
Daiichi Sankyo & AstraZeneca’s Enhertu Plus Pertuzumab Recommended for EU Approval as 1st-Line Treatment for HER2-Positive Metastatic Breast Cancer, Achieves 44% Risk Reduction in Phase III
Daiichi Sankyo Press Release Japan Overview The EMA's CHMP has recommended Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for approval as a first-line treatment for HER2-positive metastatic breast cancer in the EU. This ... -
Daiichi Sankyo’s Early ADC Pipeline Lags Rivals as Cash Flow Nears Peak, Incurs $850M Charges for Underutilized CMO Capacity
BioSpace USA Overview Jefferies analysts suggest Daiichi Sankyo's early-stage antibody-drug conjugate (ADC) pipeline is not keeping pace with rivals, despite the success of Enhertu and Datroway. Enhertu and Datroway are nearing peak reve... -
Lonza Achieves Strong H1 2026 Growth: CDMO Strategy Accelerates with Expanded ADC and High-Value Small Molecule Manufacturing
BioPharma BoardRoom Switzerland Overview Lonza CEO Wolfgang Wienand highlighted the company's strong growth in H1 2026, emphasizing the accelerating momentum of its CDMO strategy. Lonza expanded strategic long-term collaboration agreemen... -
Samsung Biologics Acquires PolyPeptide in All-Cash Offer: Accelerating Multi-Modality Strategy and Global Network Expansion
PR Newswire South Korea Overview Samsung Biologics announced an all-cash offer to acquire PolyPeptide, accelerating its multi-modality strategy and expanding its global manufacturing network across the U.S., Europe, and India. This acqui... -
FDA Approves Dato-DXd (Datroway) for Metastatic Triple-Negative Breast Cancer based on Phase III TROPION-Breast02 Trial
Cancer Network USA Overview The U.S. FDA has approved datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1/PD-L1 immune check... -
BeOne Medicines Invests $300M in New Jersey Manufacturing Expansion, Boosting Biologic, Small Molecule, and ADC Production
Fierce Pharma USA Overview BeOne Medicines announced a $300 million investment to significantly expand its manufacturing facility in New Jersey. The Hopewell campus, opened in 2024, will evolve into a fully integrated manufacturing hub, ... -
Lonza and Engitix Ink ADC License Deal for ECM-Targeted Cancer, Fibrosis Therapies
GEN (Genetic Engineering & Biotechnology News) Switzerland Overview Lonza and Engitix Ltd. have signed a licensing agreement for an Antibody-Drug Conjugate (ADC) technology platform, targeting cancer and fibrosis therapies focused on the...
